Literature DB >> 2095129

Chelators affecting iron absorption in mice.

G J Kontoghiorghes1.   

Abstract

The effect of natural and synthetic chelators on iron (59Fe) absorption in mice has been studied in three different experiments using single or repeated intragastric administrations of chelator iron (59Fe) complexes of different chelator doses. The amount of 59Fe in whole animals, their excretions and also distribution of 59Fe in blood, liver, spleen and heart was measured at one, three and eight weeks following the 59Fe-chelator administrations and compared to controls which received the same amount of iron (59Fe) but no chelator. 2-Hydroxy-4-methoxypyridine-1-oxide and maltol, which form lipophilic iron complexes, were found to cause an increase of 59Fe absorption while other chelators caused a decrease either by precipitating iron eg. 2-hydroxypyridine-1-oxide or by forming non absorbable soluble iron complexes eg. desferrioxamine, mimosine, EDTA. 1,2-Dimethyl-3-hydroxypyrid-4-one caused a decrease in iron absorption at a high dose (10 mg) by comparison to the control group but it did not significantly alter iron absorption at a lower dose (2 mg). It is suggested that natural and synthetic iron chelating compounds influence the absorption of iron and some may have a use in the treatment of diseases associated with gastro-intestinal iron absorption imbalance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095129

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  13 in total

1.  Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells.

Authors:  G J Kontoghiorghes; A May
Journal:  Biol Met       Date:  1990

2.  Dietary and pharmacological factors affecting iron absorption in mice and man (Comment for a Letter to the editor).

Authors:  Christina N Kontoghiorghe; Annita Kolnagou; George J Kontoghiorghes
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

3.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 4.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 5.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

Review 7.  Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration.

Authors:  Shalini S Rao; Paul Anthony Adlard
Journal:  Front Mol Neurosci       Date:  2018-08-17       Impact factor: 5.639

Review 8.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

9.  Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone.

Authors:  Viktor A Timoshnikov; Tatyana V Kobzeva; Nikolay E Polyakov; George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

Review 10.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.